To investigate the pharmacokinetic drug-drug interaction potential of fixed dose
antiretroviral therapies, i.e. ATRIPLA, COMPLERA, STRIBILD, TRIUMEQ, or any approved
antiretroviral protease inhibitor in combination with (preferably) TRIUMEQ, on the exposure
to riociguat in HIV patients on a stable dose of one of these therapies.
• To Assess the safety and tolerability of riociguat treatment in combination with these
fixed-dose antiretroviral therapies.
Phase:
Phase 1
Details
Lead Sponsor:
Bayer
Treatments:
Anti-Retroviral Agents Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Emtricitabine, Rilpivirine, Tenofovir Drug Combination HIV Protease Inhibitors Protease Inhibitors Riociguat Tenofovir Triumeq